BCRXBioCryst Pharmaceuticals, Inc.
Is it safe?
Solid, nothing alarming: quality strong, but heavy debt (CCC) and big price swings.
Some accounting flags, worth a closer look Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -84% · now 19% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BCRX take a bad year?
The deepest fall in BCRX's price history on file is −84%; it is 19% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 50%
Annualised volatility · roughly twice as jumpy as the market
- Worst drawdown on file
- −84%
Worst drawdown on file · −19% today
Details›
- Total debtQ2 2026
- $395M
- Cash and short-term investments
- $353M
- Net debt
- $43M
- EBITDA, trailing twelve months
- −$311M
- Operating profit, trailing twelve months
- −$313M
- Annualised volatilitytwo years of daily moves
- 50%
- Worst drawdown on file
- −84%
- Below its 52-week high
- 19%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #41 of 41 by RyuScore